---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-002092"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2025-01-22T23:59:59+00:00"
generated_at: "2026-05-27T20:50:36.267212+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Abbott Q4 organic base business sales +10.1%; FY2025 adj. EPS guidance $5.05-$5.25

## Summary
- Q4 reported sales $11.0B (+7.2% YoY); organic base business (ex-COVID) grew 10.1%.
- Q4 GAAP diluted EPS $5.27; adjusted diluted EPS $1.34 (core measure).
- Full-year 2024 sales $42.0B (+4.6% reported); organic base business +9.6%; adjusted EPS $4.67.
- Medical Devices Q4 sales $5.05B (+13.7% reported); Diabetes Care FreeStyle Libre grew 22.7% to $1.86B.
- FY2025 guidance: organic sales growth 7.5%-8.5%; adjusted EPS $5.05-$5.25; op. margin 23.5%-24.0%.

## SEC filing metadata
- accession: 0001628280-25-002092
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2025-01-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828025002092/0001628280-25-002092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828025002092/abt-20250122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-002092
- JSON: https://secwatch.observer/filing/0001628280-25-002092.json
- Plain text: https://secwatch.observer/filing/0001628280-25-002092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.